Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs...
Transcript of Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs...
![Page 1: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/1.jpg)
Non Steroideal Antinflammatory Drugs
& Cardiovascular Risk
Andrea FanelliU.O. Anestesia e Medicina Perioperatoria
Istituti Ospitalieri di Cremona
![Page 2: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/2.jpg)
NSAIDs
![Page 3: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/3.jpg)
NSAIDsare widely used since they are indicated in the
treatment of several grades of
![Page 4: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/4.jpg)
NSAIDsare widely used since they are indicated in the
treatment of several grades of
acute pain
![Page 5: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/5.jpg)
NSAIDsare widely used since they are indicated in the
treatment of several grades of
acute pain
...and inflammation
![Page 6: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/6.jpg)
![Page 7: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/7.jpg)
aceclofenac; acemetacina; acido mefenamico; acido tiaprofenico;
amtolmetina guacile; celecoxib; cinnoxicam; dexibuprofene;
diclofenac; etoricoxib; fentiazac; flurbiprofene; furprofene;
ibuprofene; indometacina; ketoprofene; Lornoxicam; meloxicam;
nabumetone; naprossene; nimesulide: oxaprozina; piroxicam;
proglumetacina; sulindac; tenoxicam...
NOTAArtropatie su base connettivitica
Osteoartrosi in fase algica o infiammatoria
Dolore neoplastico
Attacco acuto di gotta SSN
![Page 8: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/8.jpg)
time
![Page 9: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/9.jpg)
time...should be used at the lowest effective dose for the shortest possible treatment duration
arthritic conditions
rheumatoid arthritis osteoarthritis
ankylosing spondylitis acute gout
acute musculo-skeletal disorders
periarthritis tendinitis
tenosynovitis bursitis
painful conditions resulting from trauma
fracture, low back pain, sprains, strains,
dislocations, orthopaedic, dental and
other minor surgery
![Page 10: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/10.jpg)
time...should be used at the lowest effective dose for the shortest possible treatment duration
![Page 11: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/11.jpg)
time...should be used at the lowest effective dose for the shortest possible treatment duration
1st week
![Page 12: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/12.jpg)
time...should be used at the lowest effective dose for the shortest possible treatment duration
1st week
2nd week
![Page 13: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/13.jpg)
time...should be used at the lowest effective dose for the shortest possible treatment duration
1st week
2nd week
3nd week
![Page 14: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/14.jpg)
time...should be used at the lowest effective dose for the shortest possible treatment duration
1st week
2nd week
3nd weekthink t
o change
![Page 15: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/15.jpg)
GICVRHSA side effectstime
![Page 16: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/16.jpg)
GI CV R H S A
side effectstime
![Page 17: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/17.jpg)
GI CV R H S A
side effectstime
mechanisms of actionNSAIDs
![Page 18: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/18.jpg)
NSAIDs therapeutic and adverse effects
prostanoid biosynthesisprostaglandin, thromboxane A2 and prostacyclin
Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA. Prostanoids in health and disease. J. Lipid Res. 50, S423–S428 (2009).
![Page 19: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/19.jpg)
NSAIDs therapeutic and adverse effects
prostanoid biosynthesisprostaglandin, thromboxane A2 and prostacyclin
Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA. Prostanoids in health and disease. J. Lipid Res. 50, S423–S428 (2009).
![Page 20: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/20.jpg)
NSAIDs therapeutic and adverse effects
prostanoid biosynthesisprostaglandin, thromboxane A2 and prostacyclin
inflammatory reaction - resolutionerosion of cartilage & juxtaarticular bone
GI cytoprotection & ulcerationangiogenesis & cancer
hemostasis & thrombosisrenal hemodynamics & progression of kidney disease
atheroprotection & progression of atherosclerosis
Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA. Prostanoids in health and disease. J. Lipid Res. 50, S423–S428 (2009).
![Page 21: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/21.jpg)
NSAIDs therapeutic and adverse effects
prostanoid biosynthesisprostaglandin, thromboxane A2 and prostacyclin
![Page 22: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/22.jpg)
Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL.COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13926-31.
COX 1
COX 2
COX 3
NSAIDs therapeutic and adverse effects
prostanoid biosynthesisprostaglandin, thromboxane A2 and prostacyclin
![Page 23: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/23.jpg)
Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL.COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13926-31.
COX 1
cytoprotection of the gastric mucosa
normal platelet function
NSAIDs therapeutic and adverse effects
![Page 24: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/24.jpg)
Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL.COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13926-31.
COX 1
cytoprotection of the gastric mucosa
normal platelet function
adverse gastrointestinal effects and impaired platelet function
NSAIDs therapeutic and adverse effects
![Page 25: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/25.jpg)
Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL.COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13926-31.
COX 2
induced in the presence of inflammation or cell injury
PGI2 acts as a vasodilator
NSAIDs therapeutic and adverse effects
![Page 26: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/26.jpg)
Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL.COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13926-31.
COX 2
induced in the presence of inflammation or cell injury
PGI2 acts as a vasodilator
anti-inflammatory, anti-pyretic and analgesic properties
NSAIDs therapeutic and adverse effects
![Page 27: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/27.jpg)
selectivity COX-1/COX-2
![Page 28: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/28.jpg)
selectivity COX-1/COX-2
COX 2
![Page 29: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/29.jpg)
selectivity COX-1/COX-2
COX 2
Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. Jun 22;96(13):7563-8 (1999).
![Page 30: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/30.jpg)
COX-2
NSAIDs therapeutic and adverse effects
![Page 31: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/31.jpg)
COX-2
coxib
NSAIDs therapeutic and adverse effects
![Page 32: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/32.jpg)
COX-2
coxibClark D.W.J., Layton D., Shakir S.A.W. Do some inhibitors of COX-2 increase the risk of thromboembolic events? Linking pharmacology with pharmacoepidemiology. Drug Saf. (2004) 27 427–456.
Agency’s Committee for Medicinal
Products for Human Use
(CHMP)
2005
NSAIDs therapeutic and adverse effects
![Page 33: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/33.jpg)
Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL.COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13926-31.
COX 2
induced in the presence of inflammation or cell injury
PGI2 acts as a vasodilator
anti-inflammatory, anti-pyretic and analgesic properties
NSAIDs therapeutic and adverse effects
![Page 34: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/34.jpg)
Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL.COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13926-31.
COX 2
induced in the presence of inflammation or cell injury
PGI2 acts as a vasodilator
anti-inflammatory, anti-pyretic and analgesic properties
prothrombotic state
NSAIDs therapeutic and adverse effects
![Page 35: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/35.jpg)
On September 30, 2004, Merck withdrew rofecoxib from the market
US$2.5 billion
![Page 36: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/36.jpg)
On September 30, 2004, Merck withdrew rofecoxib from the market
US$2.5 billion
an old story about the peer review process
20002005
![Page 37: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/37.jpg)
A medical Madoff
Scott Reuben SAGA
![Page 38: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/38.jpg)
A medical Madoff
Scott Reuben SAGA
...at least 21 of Reuben's papers were pure fiction
![Page 39: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/39.jpg)
A medical Madoff
Scott Reuben SAGA
...at least 21 of Reuben's papers were pure fiction
Vioxx......CelebrexNeurontin...
...Lyrica
![Page 40: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/40.jpg)
What do we have?
coxib
celecoxibetoricoxib
![Page 41: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/41.jpg)
What do we have?
coxib
celecoxibetoricoxib
Insufficienza cardiaca congestizia (NYHA II-IV)
Cardiopatia ischemica, arteriopatia periferica e/o
vasculopatia cerebrale accertate.
![Page 42: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/42.jpg)
What do we have?
coxib
etoricoxib
![Page 43: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/43.jpg)
What do we have?
coxib
etoricoxib
Pazienti ipertesi in cui la pressione arteriosa è
persistentemente al di sopra di 140/90 mmHg e
non è controllata adeguatamente.
![Page 44: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/44.jpg)
daily practice
CV GI
![Page 45: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/45.jpg)
daily practice
CV GI
![Page 46: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/46.jpg)
daily practice
CV GI
68%
32%
Superior GI Inferior GI
GI bleeding79%
21%
Superior GI Inferior GI
GI perforation
![Page 47: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/47.jpg)
cardiovascular riskNSAIDs &
Agency’s Committee for Medicinal
Products for Human Use
(CHMP)
2005
![Page 48: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/48.jpg)
cardiovascular riskNSAIDs &
Agency’s Committee for Medicinal
Products for Human Use
(CHMP)
2005the benefits of NSAIDs
outweighed the risks
![Page 49: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/49.jpg)
cardiovascular riskNSAIDs &
Agency’s Committee for Medicinal
Products for Human Use
(CHMP)
2005a small increased risk ofthrombotic eventsassociated with non selective NSAIDs could not be excluded
the benefits of NSAIDs
outweighed the risks
![Page 50: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/50.jpg)
MHRA PUBLIC ASSESSMENT REPORTNon-steroidal anti-inflammatory drugs and
cardiovascular risks in the general population. (2010)
Fosbøl et al. Risk of myocardial infarction and death associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009; 85: 190–197
Garcia Rodrìguez et al. Role of dose potency in the prediction of risk of myocardial infarction associated with non-steroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 11: 1628–1636
![Page 51: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/51.jpg)
MHRA PUBLIC ASSESSMENT REPORTNon-steroidal anti-inflammatory drugs and
cardiovascular risks in the general population. (2010)
Fosbøl et al. Risk of myocardial infarction and death associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009; 85: 190–197
Garcia Rodrìguez et al. Role of dose potency in the prediction of risk of myocardial infarction associated with non-steroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 11: 1628–1636
CHMP started a new review in October 2011
![Page 52: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/52.jpg)
Garcia Rodrìguez et al. Role of dose potency in the prediction of risk of myocardial infarction associated with non-steroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 11: 1628–1636
retrospective, population-based cohort study with case-control analysis
8 852 non-fatal MI
![Page 53: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/53.jpg)
Garcia Rodrìguez et al. Role of dose potency in the prediction of risk of myocardial infarction associated with non-steroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 11: 1628–1636
retrospective, population-based cohort study with case-control analysis
8 852 non-fatal MI
All NSAIDS may be associated with a small increased risk of MIparticularly when used at high doses, for long-term treatment and in those with a history of CAD
![Page 54: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/54.jpg)
Garcia Rodrìguez et al. Role of dose potency in the prediction of risk of myocardial infarction associated with non-steroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 11: 1628–1636
retrospective, population-based cohort study with case-control analysis
8 852 non-fatal MI
All NSAIDS may be associated with a small increased risk of MIparticularly when used at high doses, for long-term treatment and in those with a history of CAD
Diclofenac has a thrombotic profile that shows greater similarity to the coxibs
Dose ≥100 mg per day may be associated with an increase in MI risk.
![Page 55: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/55.jpg)
Garcia Rodrìguez et al. Role of dose potency in the prediction of risk of myocardial infarction associated with non-steroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 11: 1628–1636
retrospective, population-based cohort study with case-control analysis
8 852 non-fatal MI
All NSAIDS may be associated with a small increased risk of MIparticularly when used at high doses, for long-term treatment and in those with a history of CAD
Ibuprofen does not increase the risk of MI at low doses but at high doses a risk similar to that of coxibs has been
observed
![Page 56: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/56.jpg)
Garcia Rodrìguez et al. Role of dose potency in the prediction of risk of myocardial infarction associated with non-steroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 11: 1628–1636
retrospective, population-based cohort study with case-control analysis
8 852 non-fatal MI
All NSAIDS may be associated with a small increased risk of MIparticularly when used at high doses, for long-term treatment and in those with a history of CAD
Naproxen is associated with a lower risk of MI than ibuprofen and diclofenac and at low doses is not associated with any discernable increase in risk
![Page 57: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/57.jpg)
Garcia Rodrìguez et al. Role of dose potency in the prediction of risk of myocardial infarction associated with non-steroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 11: 1628–1636
retrospective, population-based cohort study with case-control analysis
8 852 non-fatal MI
All NSAIDS may be associated with a small increased risk of MIparticularly when used at high doses, for long-term treatment and in those with a history of CAD
Naproxen is associated with a lower risk of MI than ibuprofen and diclofenac and at low doses is not associated with any discernable increase in risk
risk does not increase in association with use of NSAIDs for <30 days and that risk falls to baseline values within 3 months of stopping
![Page 58: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/58.jpg)
Fosbøl et al. Risk of myocardial infarction and death associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009; 85: 190–197
healthy individuals
hospital admission or use of co-medication
![Page 59: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/59.jpg)
Fosbøl et al. Risk of myocardial infarction and death associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009; 85: 190–197
healthy individuals
hospital admission or use of co-medication
![Page 60: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/60.jpg)
Fosbøl et al. Risk of myocardial infarction and death associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009; 85: 190–197
healthy individuals
hospital admission or use of co-medication
![Page 61: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/61.jpg)
Fosbøl et al. Risk of myocardial infarction and death associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009; 85: 190–197
healthy individuals
hospital admission or use of co-medication
![Page 62: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/62.jpg)
MHRA PUBLIC ASSESSMENT REPORTNon-steroidal anti-inflammatory drugs and
cardiovascular risks in the general population. (2010)
Fosbøl et al. Risk of myocardial infarction and death associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009; 85: 190–197
Garcia Rodrìguez et al. Role of dose potency in the prediction of risk of myocardial infarction associated with non-steroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 11: 1628–1636
CHMP started a new review in October 2011
![Page 63: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/63.jpg)
CHMP started a new review in October 2011
![Page 64: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/64.jpg)
CHMP started a new review in October 2011
Naproxen and Ibuprofenthe current treatment advice adequately reflects the knowledge
regarding the safety and efficacy of these medicines
![Page 65: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/65.jpg)
CHMP started a new review in October 2011
Diclofenacthe latest evidence appears to show a consistent but small
increase in the risk of cardiovascular side effects compared with other NSAIDs, similar to the risks of COX-2 inhibitors
![Page 66: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/66.jpg)
CHMP started a new review in October 2011
Diclofenacthe latest evidence appears to show a consistent but small
increase in the risk of cardiovascular side effects compared with other NSAIDs, similar to the risks of COX-2 inhibitors
![Page 67: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/67.jpg)
Hepatic reactionsnimesulide
![Page 68: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/68.jpg)
Hepatic reactionsnimesulide
2003: maximum daily dose: 100 mg BID for a short a duration as possible Acute Pain
2007: the CHMP concluded that the data did not support a suspension of all marketing authorisations in Europe15
![Page 69: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/69.jpg)
Da#$OsMed$$
0"
1"
2"
3"
4"
5"
6"
7"
8"
9"
2002" 2003" 2004" 2005" 2006" 2007" 2008" 2009" 2010"
Consum
o'DDD/1000'ab
/die'
Consumo'DDD/1000'ab'die10'
Nimesulide" Ketoprofene" Ibuprofene" Diclofenac"
Nimesulide)
Diclofenac)
Ketoprofene)
Ibuprofene)
2011OsMed
20#
25#
30#
35#
40#
45#
50#
55#
60#
65#
70#
2002# 2003# 2004# 2005# 2006# 2007# 2008# 2009# 2010# 2011#
Consum
o#DDD/1000#ab
/die#
Consumo#DDD/1000#ab/die#–#An;acidi#e#An;ulcera10#
Variazione#annua#media#200242007##+11,1%#
Variazione#annua#media#200742010#+14,4%#
Dal#2007,#la#variazione#annua#media#del#consumo#di#
an;acidi#ed#an;ulcera#ha#subito#un'accelerazione#di#
+3,3#pun;#
FANS#
![Page 70: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/70.jpg)
Da#$OsMed$$
0"
1"
2"
3"
4"
5"
6"
7"
8"
9"
2002" 2003" 2004" 2005" 2006" 2007" 2008" 2009" 2010"
Consum
o'DDD/1000'ab
/die'
Consumo'DDD/1000'ab'die10'
Nimesulide" Ketoprofene" Ibuprofene" Diclofenac"
Nimesulide)
Diclofenac)
Ketoprofene)
Ibuprofene)
2011OsMed
20#
25#
30#
35#
40#
45#
50#
55#
60#
65#
70#
2002# 2003# 2004# 2005# 2006# 2007# 2008# 2009# 2010# 2011#
Consum
o#DDD/1000#ab
/die#
Consumo#DDD/1000#ab/die#–#An;acidi#e#An;ulcera10#
Variazione#annua#media#200242007##+11,1%#
Variazione#annua#media#200742010#+14,4%#
Dal#2007,#la#variazione#annua#media#del#consumo#di#
an;acidi#ed#an;ulcera#ha#subito#un'accelerazione#di#
+3,3#pun;#
FANS#
nimesulide
2007
![Page 71: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/71.jpg)
n 8
Diclofenac
![Page 72: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/72.jpg)
low dose Aspirin
Mechanism of cardiovascular increased risk of NSAIDs
25%secondary
incidence of MI& Stroke
Patrignani P, Tacconelli S, Bruno A, Sostres C, Lanas A. Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Expert Rev Clin Pharmacol. Sep;4(5):605-21 (2011).
![Page 73: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/73.jpg)
low dose Aspirin
Mechanism of cardiovascular increased risk of NSAIDs
25%secondary
incidence of MI& Stroke
95%TXA2
Patrignani P, Tacconelli S, Bruno A, Sostres C, Lanas A. Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Expert Rev Clin Pharmacol. Sep;4(5):605-21 (2011).
![Page 74: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/74.jpg)
Mechanism of cardiovascular increased risk of NSAIDs
nNSAIDs & coxib
PGI2
COX-2
Patrignani P, Tacconelli S, Bruno A, Sostres C, Lanas A. Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Expert Rev Clin Pharmacol. Sep;4(5):605-21 (2011).
![Page 75: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/75.jpg)
Mechanism of cardiovascular increased risk of NSAIDs
nNSAIDs & coxib
PGI2
COX-2
increased platelet reactivity
Patrignani P, Tacconelli S, Bruno A, Sostres C, Lanas A. Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Expert Rev Clin Pharmacol. Sep;4(5):605-21 (2011).
![Page 76: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/76.jpg)
Mechanism of cardiovascular increased risk of NSAIDs
nNSAIDs & coxib
PGI2
COX-2
increased platelet reactivity
95%TXA2
Patrignani P, Tacconelli S, Bruno A, Sostres C, Lanas A. Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Expert Rev Clin Pharmacol. Sep;4(5):605-21 (2011).
![Page 77: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/77.jpg)
Garcia Rodrìguez et al. Role of dose potency in the prediction of risk of myocardial infarction associated with non-steroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 11: 1628–1636
![Page 78: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/78.jpg)
Mechanism of cardiovascular increased risk of NSAIDs
Garcia Rodrìguez et al. Role of dose potency in the prediction of risk of myocardial infarction associated with non-steroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 11: 1628–1636
![Page 79: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/79.jpg)
Mechanism of cardiovascular increased risk of NSAIDs
Garcia Rodrìguez et al. Role of dose potency in the prediction of risk of myocardial infarction associated with non-steroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 11: 1628–1636
Diclofenac dose &CV risk
![Page 80: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/80.jpg)
Mechanism of cardiovascular increased risk of NSAIDs
Garcia Rodrìguez et al. Role of dose potency in the prediction of risk of myocardial infarction associated with non-steroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 11: 1628–1636
Diclofenac dose &CV risk
half-life and type of formulations
25
![Page 81: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/81.jpg)
diclofenac and etoricoxib together account for
approximately one-third of all sales of NSAIDs
McGettigan P, Henry D. Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med. 2013 Feb;10(2):e1001388. doi: 10.1371/journal.pmed.1001388. Epub 2013 Feb 12.
![Page 82: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/82.jpg)
GI adverse reactionsNSAIDs
the most frequent reactions related to NSAIDs
![Page 83: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/83.jpg)
GI adverse reactionsNSAIDs
![Page 84: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/84.jpg)
OsMed2012
January-September
![Page 85: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/85.jpg)
OsMed2012
January-September
![Page 86: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/86.jpg)
OsMed2012
January-September
![Page 87: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/87.jpg)
OsMed2012
January-September
Top 30
![Page 88: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/88.jpg)
OsMed2012
January-September
Top 30
self medication?
![Page 89: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/89.jpg)
...are quite uncommon when compared with other
pharmacological classes
hepatic reactionsNSAIDs
Hussaini S.H., Farrington E.A. Idiosyncratic drug-induced liver injury: an overview. Expert Opin. Drug Saf. 6 673–684 (2007).
![Page 90: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/90.jpg)
efficacy
GICVRHSA
![Page 91: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/91.jpg)
efficacy
GI CV R H S A
![Page 92: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/92.jpg)
efficacy
GI CV R H S A
the benefits of NSAIDs outweighed the risks
![Page 93: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/93.jpg)
“fragile” patient
![Page 94: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/94.jpg)
“fragile” patient
GI CV H R
![Page 95: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/95.jpg)
“fragile” patient
GI CV H R
![Page 96: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/96.jpg)
“fragile” patient
GI CV H R
3.3-4.3% 2.2-2.8% 1.1-2.1% 1.1-2.1%
![Page 97: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/97.jpg)
![Page 98: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/98.jpg)
General Rules
![Page 99: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/99.jpg)
General Ruleslowest effective dose for the shortest period of time
![Page 100: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/100.jpg)
General Ruleslowest effective dose for the shortest period of timeavoid corticosteroids, anticoagulants, low-dose aspirin or antiplatelet agents
![Page 101: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/101.jpg)
General Ruleslowest effective dose for the shortest period of timeavoid corticosteroids, anticoagulants, low-dose aspirin or antiplatelet agents
Use ‘safer’ NSAIDs (coxibs, diclofenac, nimesulide and ibuprofen)
![Page 102: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/102.jpg)
General Ruleslowest effective dose for the shortest period of timeavoid corticosteroids, anticoagulants, low-dose aspirin or antiplatelet agents
Use ‘safer’ NSAIDs (coxibs, diclofenac, nimesulide and ibuprofen)
Less use of NSAIDs with the highest GI toxicity (ketorolac, piroxicam, and ketoprofen)
![Page 103: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/103.jpg)
CV
![Page 104: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/104.jpg)
CV
avoid coxib and high dose of Diclofenac and Ibuprofen
![Page 105: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/105.jpg)
CV
avoid coxib and high dose of Diclofenac and Ibuprofen
?Aspirin
![Page 106: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/106.jpg)
CV
?Aspirin
![Page 107: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/107.jpg)
CV
?Aspirin
naproxen
![Page 108: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/108.jpg)
CV & GI
NSAIDs
![Page 109: Non Steroideal Antinflammatory Drugs & Cardiovascular Risk · Non Steroideal Antinflammatory Drugs & Cardiovascular Risk Andrea Fanelli U.O. Anestesia e Medicina Perioperatoria Istituti](https://reader031.fdocuments.net/reader031/viewer/2022022723/5c6a304f09d3f20f298c3159/html5/thumbnails/109.jpg)
time...should be used at the lowest effective dose for the shortest possible treatment duration
1st week
2nd week
3nd week